President Trump recently signed a pair of bills into law aimed at increasing transparency with regard to drug prices in the United States. The Patient Right to Know Drug Prices Act (S. 2554) and the Know the Lowest Price Act (S. 2553) prohibit so-called "gag clauses," which prevent pharmacists from telling customers if they could save money by buying prescription drugs out-of-pocket rather than using their health insurance. S. 2554 applies to private health plans, while S. 2553 targets Medicare Part D and Medicare Advantage plans.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
In the latest ASCO in Action Podcast, Dr. Ray Page, DO, PhD, FACOI joins ASCO CEO Dr. Clifford A. Hudis to discuss the impact that Pharmacy Benefit Managers (PBMs) are having on cancer care delivery and ASCO’s recent position statement on PBMs.
In the latest ASCO in Action Podcast, Manali Patel, MD, MPH, joined ASCO CEO Dr. Clifford A. Hudis to discuss ASCO’s position statement on Medicaid work requirements, which addresses state waivers submitted to the Centers for Medicare & Medicaid Services (CMS) that, if approved, would make Medicaid eligibility, continued coverage, cost-sharing, and other program benefits dependent on a beneficiary’s work status.
The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.
In a new position statement, the American Society of Clinical Oncology (ASCO) warns that some of the practices of pharmacy benefit manager (PBM) companies use could hinder patient access to timely, high-quality cancer care. ASCO describes a range of PBM practices that, while they may be intended to help control costs in cancer care, might compromise physicians’ ability to provide the right treatment at the right time for people with cancer.
ASCO strongly opposes the Centers for Medicare & Medicaid Services (CMS) decision to allow Medicare Advantage plans to employ step therapy across physician-administered and self-administered drugs under Medicare Part B and Part D.
ASCO strongly opposes provisions in the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule that could significantly cut cancer care resources that are needed to provide high-quality care to individuals with cancer
ASCO President Monica M. Bertagnolli, MD, FACS, FASCO joined ASCO CEO Dr. Clifford A. Hudis in the most recent ASCO in Action Podcast to discuss her presidential theme and the vision she has for ASCO this coming year.
In the latest ASCO in Action Podcast, Dr. Edward Kim, Chair of the Department of Solid Tumor Oncology at the Levine Cancer Institute, joined ASCO CEO Dr. Clifford A. Hudis to discuss eligibility criteria for cancer clinical trials.
The American Medical Association (AMA) Opioid Task Force issued a report documenting physician-driven initiatives to advance the fight against the opioid epidemic in the United States, progress to date, and recommendations to continue to help reverse the epidemic. ASCO has been an active member of the AMA Opioid Task Force since 2017.
The Centers for Medicare & Medicaid Services (CMS) has provided an update on their review of a 2017 Wisconsin Physician Service Insurance Corporation (WPS)—a Medicare Administrative Contractor (MAC)—local coverage decision limiting off-label prescribing.
During the American Medical Association (AMA) House of Delegates (HOD) annual meeting, delegates approved several ASCO-led resolutions and incorporated them into the AMA’s policy agenda.
Right-to-try is the latest topic addressed in the ASCO in Action podcast series. ASCO CEO Dr. Clifford Hudis recently interviewed ASCO Senior Vice President and Chief Medical Officer Dr. Richard Schilsky to examine RTT legislation—now enacted as federal law—and discuss the Food and Drug Administration’s (FDA) expanded access program.
From June 9 – 13, ASCO’s delegates will participate in the American Medical Association’s (AMA) Annual Meeting of the House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA, and meets twice a year to discuss pressing issues and establish association policies. ASCO currently sends three delegates to the AMA HOD: Edward P. Balaban, DO, FACP, FASCO; Thomas A. Marsland, MD, FASCO; and Ray D. Page, DO, PhD, FACOI.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to a proposed rule to revise the agency’s methods for assuring patient access to Medicaid services. In a letter to CMS Administrator Seema Verma, ASCO President Bruce Johnson, MD, FASCO, urged CMS to maintain its rule requiring states to monitor and report on beneficiary access to providers, and to ensure that final changes do not jeopardize access to care for patients with cancer. ASCO also encouraged CMS to explicitly require state assessment of access to oncologists.